Spots Global Cancer Trial Database for adult acute erythroid leukemia (m6)
Every month we try and update this database with for adult acute erythroid leukemia (m6) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia | NCT00002549 | Leukemia | filgrastim busulfan cyclophosphamid... cytarabine daunorubicin hy... etoposide idarubicin mesna mitoxantrone hy... allogeneic bone... autologous bone... peripheral bloo... radiation thera... | 15 Years - 60 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia | NCT00004128 | Leukemia | aldesleukin filgrastim busulfan cyclophosphamid... cytarabine daunorubicin hy... etoposide autologous bone... peripheral bloo... radiation thera... | 15 Years - 60 Years | National Cancer Institute (NCI) | |
| Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission | NCT00070135 | Adult Acute Mye... Acute Myeloid L... | filgrastim Anti-Thymocyte ... busulfan fludarabine pho... methotrexate tacrolimus Allogeneic Hema... | 60 Years - 74 Years | Alliance for Clinical Trials in Oncology | |
| Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia | NCT00002588 | Leukemia | etoposide topotecan hydro... | 18 Years - | Case Comprehensive Cancer Center | |
| Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission | NCT00002768 | Leukemia | filgrastim busulfan cytarabine etoposide methotrexate peripheral bloo... | 15 Years - 69 Years | Alliance for Clinical Trials in Oncology | |
| S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT00004217 | Leukemia | filgrastim sargramostim cytarabine daunorubicin hy... valspodar | 56 Years - | SWOG Cancer Research Network | |
| Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT00003268 | Drug/Agent Toxi... Leukemia | amifostine trih... cytarabine idarubicin | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia | NCT00003758 | Leukemia | cytarabine idarubicin allogeneic bone... autologous bone... peripheral bloo... | 15 Years - 60 Years | National Cancer Institute (NCI) | |
| Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia | NCT00004215 | Anemia Leukemia Neutropenia Thrombocytopeni... | filgrastim leridistim cytarabine daunorubicin hy... | 55 Years - | Memorial Sloan Kettering Cancer Center | |
| Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | NCT00006122 | Leukemia | cytarabine etoposide gemtuzumab ozog... idarubicin mitoxantrone hy... | 61 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | NCT00027872 | Acute Myeloid L... Adult Acute Bas... Adult Acute Eos... Adult Acute Ery... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Cellular Diagno... Untreated Adult... | tipifarnib laboratory biom... | 65 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia | NCT00002549 | Leukemia | filgrastim busulfan cyclophosphamid... cytarabine daunorubicin hy... etoposide idarubicin mesna mitoxantrone hy... allogeneic bone... autologous bone... peripheral bloo... radiation thera... | 15 Years - 60 Years | National Cancer Institute (NCI) | |
| Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia | NCT00052299 | Leukemia | cytarabine etoposide gemtuzumab ozog... idarubicin mitoxantrone hy... | 61 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Total-Body Irradiation Plus Stem Cell Transplantation And White Blood Cell Infusion in Treating Older Patients With Acute Myeloid Leukemia | NCT00005801 | Leukemia | therapeutic all... peripheral bloo... radiation thera... | 55 Years - 74 Years | University of Colorado, Denver | |
| Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | NCT00027872 | Acute Myeloid L... Adult Acute Bas... Adult Acute Eos... Adult Acute Ery... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Cellular Diagno... Untreated Adult... | tipifarnib laboratory biom... | 65 Years - | National Cancer Institute (NCI) | |
| Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia | NCT00005962 | Leukemia | sargramostim cyclophosphamid... cytarabine gemtuzumab ozog... liposomal dauno... topotecan hydro... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia | NCT00003405 | Leukemia | recombinant int... amifostine trih... bromodeoxyuridi... cytarabine idarubicin idoxuridine isotretinoin mitoxantrone hy... | 0 Years - 70 Years | Rush University Medical Center | |
| Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome | NCT00002547 | Leukemia Myelodysplastic... | busulfan cyclophosphamid... cyclosporine cytarabine methotrexate allogeneic bone... syngeneic bone ... | - 60 Years | Barbara Ann Karmanos Cancer Institute | |
| Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia | NCT00002658 | Leukemia Neutropenia | filgrastim amsacrine cyclophosphamid... cytarabine daunorubicin hy... etoposide idarubicin mitoxantrone hy... thioguanine tretinoin allogeneic bone... autologous bone... peripheral bloo... radiation thera... | 15 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia | NCT00006363 | Adult Acute Bas... Adult Acute Eos... Adult Acute Ery... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Myelo... de Novo Myelody... Untreated Adult... Untreated Child... | cytarabine daunorubicin hy... etoposide valspodar filgrastim busulfan autologous hema... peripheral bloo... aldesleukin clinical observ... pharmacological... | 15 Years - 59 Years | National Cancer Institute (NCI) | |
| Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia | NCT00005962 | Leukemia | sargramostim cyclophosphamid... cytarabine gemtuzumab ozog... liposomal dauno... topotecan hydro... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| flt3L in Treating Patients With Acute Myeloid Leukemia | NCT00006223 | Leukemia | recombinant flt... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia | NCT00003405 | Leukemia | recombinant int... amifostine trih... bromodeoxyuridi... cytarabine idarubicin idoxuridine isotretinoin mitoxantrone hy... | 0 Years - 70 Years | Rush University Medical Center | |
| Total-Body Irradiation Plus Stem Cell Transplantation And White Blood Cell Infusion in Treating Older Patients With Acute Myeloid Leukemia | NCT00005801 | Leukemia | therapeutic all... peripheral bloo... radiation thera... | 55 Years - 74 Years | University of Colorado, Denver | |
| Vorinostat in Treating Patients With Acute Myeloid Leukemia | NCT00305773 | Adult Acute Ery... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Recurrent Adult... Refractory Cyto... Secondary Acute... Untreated Adult... | vorinostat vorinostat | 18 Years - | National Cancer Institute (NCI) | |
| S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML | NCT00085709 | Leukemia | gemtuzumab ozog... observation Cytosine arabin... Daunomycin | 18 Years - 60 Years | SWOG Cancer Research Network | |
| Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | NCT00053144 | Leukemia | cytarabine irinotecan hydr... | 15 Years - | Roswell Park Cancer Institute | |
| S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia | NCT00049179 | Leukemia | cytarabine gemtuzumab ozog... | 18 Years - | SWOG Cancer Research Network | |
| High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia | NCT00002945 | Leukemia | aldesleukin filgrastim cyclophosphamid... cytarabine etoposide idarubicin melphalan peripheral bloo... radiation thera... | 25 Years - | Roswell Park Cancer Institute | |
| Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | NCT00006122 | Leukemia | cytarabine etoposide gemtuzumab ozog... idarubicin mitoxantrone hy... | 61 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission | NCT00070135 | Adult Acute Mye... Acute Myeloid L... | filgrastim Anti-Thymocyte ... busulfan fludarabine pho... methotrexate tacrolimus Allogeneic Hema... | 60 Years - 74 Years | Alliance for Clinical Trials in Oncology | |
| High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in Remission | NCT00002567 | Bone Marrow Abl... Leukemia | filgrastim etoposide peripheral bloo... low-LET electro... low-LET photon ... | 16 Years - 65 Years | Memorial Sloan Kettering Cancer Center | |
| CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT02019069 | Adult Acute Ery... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Myelo... | liposomal cytar... | 60 Years - | Stanford University | |
| Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | NCT00006122 | Leukemia | cytarabine etoposide gemtuzumab ozog... idarubicin mitoxantrone hy... | 61 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | NCT00027872 | Acute Myeloid L... Adult Acute Bas... Adult Acute Eos... Adult Acute Ery... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Cellular Diagno... Untreated Adult... | tipifarnib laboratory biom... | 65 Years - | National Cancer Institute (NCI) | |
| High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in Remission | NCT00002567 | Bone Marrow Abl... Leukemia | filgrastim etoposide peripheral bloo... low-LET electro... low-LET photon ... | 16 Years - 65 Years | Memorial Sloan Kettering Cancer Center | |
| S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy | NCT01360125 | Leukemia | proteomic profi... flow cytometry laboratory biom... | 18 Years - 60 Years | SWOG Cancer Research Network | |
| Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia | NCT00006045 | Leukemia | lintuzumab cytarabine etoposide mitoxantrone hy... | 18 Years - | National Cancer Institute (NCI) | |
| Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia | NCT00046930 | Leukemia Myelodysplastic... | filgrastim sargramostim cytarabine daunorubicin hy... zosuquidar trih... Placebo | 60 Years - | Eastern Cooperative Oncology Group | |
| Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | NCT00053144 | Leukemia | cytarabine irinotecan hydr... | 15 Years - | Roswell Park Cancer Institute | |
| Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia | NCT00052299 | Leukemia | cytarabine etoposide gemtuzumab ozog... idarubicin mitoxantrone hy... | 61 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | NCT00027872 | Acute Myeloid L... Adult Acute Bas... Adult Acute Eos... Adult Acute Ery... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Cellular Diagno... Untreated Adult... | tipifarnib laboratory biom... | 65 Years - | National Cancer Institute (NCI) | |
| S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy | NCT01360125 | Leukemia | proteomic profi... flow cytometry laboratory biom... | 18 Years - 60 Years | SWOG Cancer Research Network | |
| Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia | NCT00046930 | Leukemia Myelodysplastic... | filgrastim sargramostim cytarabine daunorubicin hy... zosuquidar trih... Placebo | 60 Years - | Eastern Cooperative Oncology Group | |
| Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia | NCT00003758 | Leukemia | cytarabine idarubicin allogeneic bone... autologous bone... peripheral bloo... | 15 Years - 60 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia | NCT00006363 | Adult Acute Bas... Adult Acute Eos... Adult Acute Ery... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Myelo... de Novo Myelody... Untreated Adult... Untreated Child... | cytarabine daunorubicin hy... etoposide valspodar filgrastim busulfan autologous hema... peripheral bloo... aldesleukin clinical observ... pharmacological... | 15 Years - 59 Years | National Cancer Institute (NCI) | |
| Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome | NCT00005593 | Leukemia Myelodysplastic... | carboplatin fludarabine pho... topotecan hydro... | 12 Years - | Case Comprehensive Cancer Center | |
| Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia | NCT00002925 | Leukemia | ara-C Daunorubicin Etoposide PSC-833 Aldesleukin | 15 Years - 59 Years | National Cancer Institute (NCI) | |
| S9031-S9126-S9333-S9500-A, Studying Bone Marrow and Blood Samples From Patients With Acute Myeloid Leukemia | NCT00899171 | Leukemia | DNA analysis DNA methylation... RNA analysis gene expression... reverse transcr... laboratory biom... | 18 Years - | SWOG Cancer Research Network | |
| S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy | NCT01360125 | Leukemia | proteomic profi... flow cytometry laboratory biom... | 18 Years - 60 Years | SWOG Cancer Research Network | |
| A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide | NCT00005793 | Leukemia | Cytarabine Daunorubicin Etoposide Topotecan | 16 Years - 59 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome | NCT00005593 | Leukemia Myelodysplastic... | carboplatin fludarabine pho... topotecan hydro... | 12 Years - | Case Comprehensive Cancer Center | |
| S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia | NCT00023777 | Leukemia | filgrastim sargramostim cytarabine daunorubicin hy... | 56 Years - | SWOG Cancer Research Network | |
| Total-Body Irradiation Plus Stem Cell Transplantation And White Blood Cell Infusion in Treating Older Patients With Acute Myeloid Leukemia | NCT00005801 | Leukemia | therapeutic all... peripheral bloo... radiation thera... | 55 Years - 74 Years | University of Colorado, Denver | |
| Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia | NCT00002658 | Leukemia Neutropenia | filgrastim amsacrine cyclophosphamid... cytarabine daunorubicin hy... etoposide idarubicin mitoxantrone hy... thioguanine tretinoin allogeneic bone... autologous bone... peripheral bloo... radiation thera... | 15 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
